News Agency
The Times

PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore

  • Written by Media Outreach

Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.

SINGAPORE - Media OutReach - 6 June 2022- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that PADCEV (enfortu...

Read more: PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer...

Executive Recruitment And The Value Of Executive Recruitment Agencies In Modern Hiring

Finding the right leadership talent is one of the most important decisions an organisation can make. Strong leaders influence company culture, business performance, strategic direction, and long-term growth. As competition for experienced executives continues to increase, executive recruitment has become a... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion